Revive
Therapeutics Partners with Supriya
to Pursue EUA for
Bucillamine
to
Treat COVID in India
TORONTO,
June
8,
2021 --
InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive" or the
"Company") (CSE: RVV, USA: RVVTF, Frankfurt:
31R), a specialty life
sciences company focused on the research and development of
therapeutics for medical needs and rare disorders,
is
pleased to announce
it
has entered into a
memorandum of
understanding dated June 7,
2021 with
Supriya
Lifescience
Ltd.
("Supriya"),
a specialty
pharmaceutical company based in
India, to
pursue
manufacturing
of the
API, conducting
clinical
registration and commercialization for Bucillamine
to treat
COVID-19 through Emergency Use Authorization
("EUA")
in India. The
relationship also sets the
foundation for Revive to expand commercialization efforts
globally by leveraging
Supriya's
extensive
manufacturing and
commercial network and Revive's
ongoing
US
FDA Phase 3 clinical
study results
of
Bucillamine to treat mild-to-moderate COVID-19.
"While our Phase 3
clinical study for COVID-19 is ongoing in the USA,
we
are
laying
the ground work by partnering with
Supriya to
execute on
our
global
manufacturing and
commercialization plans
and
leveraging their regulatory expertise
and
commercial reach
with
78
countries
they currently
supply
pharmaceutical products to," said Michael
Frank, CEO of Revive. "We are focused on
completing our current
Phase
3 study
in
the USA
and
also
obtaining
EUA.
These results
will
support drug approval
registrations
globally,
including India,
Europe,
and
Canada."
Dr. Satish
Wagh,
CMD, Supriya
Lifescience
Ltd.
said,
"Through this
collaboration, we aim to join our forces with Revive
to accelerate access to
Bucillamine in
India at
a time when it is most needed. This is a step towards making
more treatment options available to patients in India
in
dealing
with the pandemic.
With this partnership, Supriya
aims
to
enter into a niche area of chemistry and products thereby
bolstering its CMO
and
research
capabilities."
The Company is not making any express or implied claims that its
product has the ability to eliminate or cure COVID-19 (SARS-2
Coronavirus) at this time.
About
Supriya
Lifescience
Ltd.
Based
in Mumbai,
India,
Supriya
Lifescience
Ltd.
is
EUGMP
and
USFDA
approved
manufacturer
and
supplier of active pharmaceuticals ingredients
and pharmaceutical products.
Supriya
exports
to 78
countries
(in
Fiscal 2021) and
has
niche
product offerings of 39 APIs focused on
diverse therapeutic segments such as antihistamine,
analgesic, anesthetic,
vitamin, anti-asthmatic and anti-allergic.
Supriya's
manufacturing
facility is approved
by various international
regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA,
ANVISA, KFDA, PMDA, TGA
and Taiwan FDA. For
more information, visit
www.supriyalifescience.com.
About
Revive Therapeutics Ltd.
Revive is
a life sciences company focused on the research and development of
therapeutics for infectious diseases and rare disorders, and it is
prioritizing drug development efforts to take advantage of several
regulatory incentives awarded by the FDA such as Orphan Drug, Fast
Track, Breakthrough Therapy and Rare Pediatric Disease
designations. Currently, the Company is exploring the use of
Bucillamine for the potential treatment of infectious diseases,
with an initial focus on severe influenza and COVID-19. With its
recent acquisition of Psilocin Pharma Corp., Revive is advancing
the development of Psilocybin-based therapeutics in various
diseases and disorders. Revive's cannabinoid pharmaceutical
portfolio focuses on rare inflammatory diseases and the company was
granted FDA orphan drug status designation for the use of
Cannabidiol (CBD) to treat
autoimmune hepatitis (liver disease) and to treat ischemia and
reperfusion injury from organ transplantation. For more
information, visit
www.ReviveThera.com.
For more information,
please contact:
Michael
Frank
Chief
Executive Officer
Revive
Therapeutics Ltd.
Tel: 1
888 901 0036
Email: mfrank@revivethera.com
Website:
www.revivethera.com
Neither
the Canadian Securities Exchange nor its Regulation Services
Provider has reviewed or accepts responsibility for the adequacy or
accuracy of this release.
Cautionary
Statement
This
press release contains 'forward-looking information' within the
meaning of applicable Canadian securities legislation. These
statements relate to future events or future performance. The use
of any of the words "could", "intend", "expect", "believe", "will",
"projected", "estimated" and similar expressions and statements
relating to matters that are not historical facts are intended to
identify forward-looking information and are based on Revive's
current belief or assumptions as to the outcome and timing of such
future events. Forward looking information in this press release
includes information with respect to the the
Company's
cannabinoids, psychedelics and infectious diseases
programs.
Forward-looking information is based on reasonable assumptions that
have been made by Revive at the date of the information and is
subject to known and unknown risks, uncertainties, and other
factors that may cause actual results or events to differ
materially from those anticipated in the forward-looking
information. Given these risks, uncertainties and assumptions, you
should not unduly rely on these forward-looking statements. The
forward-looking information contained in this press release is made
as of the date hereof, and Revive is not obligated to update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable securities laws. The foregoing statements expressly
qualify any forward-looking information contained herein. Reference
is made to the risk factors disclosed under the heading "Risk
Factors" in the Company's annual MD&A for the fiscal year ended
June 30, 2020, which has been filed on SEDAR and is available under
the Company's profile at www.sedar.com.
Supriya
Lifescience
Limited
is proposing, subject to receipt of requisite approvals, market
conditions and other considerations, an initial public offering of
its equity shares (the "Equity
Shares")
and has filed a draft red herring prospectus dated May 15, 2021
(the "DRHP")
with the Securities and Exchange Board of India ("SEBI")
and with
the Registrar of Companies, Maharashtra at Mumbai. The DRHP is
available on the website of SEBI at www.sebi.gov.in and the website
of the Lead Managers at www.icicisecurities.com and
www.axiscapital.co.in, and the websites of BSE Limited and National
Stock Exchange of India Limited at www.bseindia.com and
www.nseindia.com,
respectively.